Metavention is a venture-backed medical device company based in Minneapolis, Minnesota that is leveraging unique insights into the role of the sympathetic nervous system in diabetes to develop Metabolic Neuromodulation Therapy (MNT). MNT is a minimally invasive cardiovascular procedure that involves passing a catheter into the arteries surrounding the liver and delivering energy to disrupt nearby nerves. Significant animal testing has demonstrated that disrupting these nerves can restore the liver to a more normal state of glucose processing and aid in the control of hyperglycemia. Our goal is to develop a safe and effective treatment that can aid patients with type 2 diabetes who are struggling to control their blood sugar with lifestyle modification and non-insulin antidiabetic agents. Metavention is currently conducting the COMPLEMENT study, a multi-center clinical trial of Metabolic Neuromodulation therapy at five sites in New Zealand. Metabolic Neuromodulation Therapy is not yet commercially approved.
Metavention Leadership / Bios
Chief Executive Officer
Kevin Hykes is CEO of Metavention, Inc. and an Operating Partner at Versant Ventures. Kevin was previously President and Chief Executive Officer of Cameron Health, developer of the first and only subcutaneous implantable defibrillator, until its acquisition by Boston Scientific in 2012. Prior to Cameron Health, he was the Chief Commercial Officer of Visiogen, Inc., a venture-backed ophthalmology company which was acquired by Abbott Medical Optics in October of 2009. Previous to Visiogen, he spent sixteen years at Medtronic, where he held leadership positions in the CRM, Neurological, Heart Valve, and Cardiac Surgery businesses in the US and Europe. Kevin received his MBA from Northwestern University and a BBA from the University of Wisconsin, and is an independent director of Hansen Medical, Inc (HNSN).
Bobak Azamian MD, DPhil
President & Chief Medical Officer
Bobby Azamian is the Founder, President and Chief Medical Officer of Metavention. Bobby joined Versant Ventures in 2011, and while at Versant founded Metavention and served as its first President and Chief Executive Officer. Prior to joining Versant, Bobby was a Senior Associate at Third Rock Ventures, where he was actively involved in the building and launch of the firm’s first medical device companies. Previously, Bobby completed residency in internal medicine and practiced as a hospitalist at Brigham and Women’s Hospital while on the faculty of Harvard Medical School. Bobby holds an MD from the Harvard-MIT Division of Health Sciences and Technology; a DPhil in Chemistry from Oxford University as a Rhodes Scholar; and a BA in Physics from Rice University.
Vice President of Research & Development
Tony Vrba is the Vice President of Research and Development of Metavention, Inc. Previously, Tony was the Senior Vice President of Product Development and General Manager at Devicix, a multi-disciplinary engineering firm that delivers innovative design solutions and comprehensive product development services to the medical device industry.
Prior to Devicix, Tony spent over 20 years in the Cardiovascular Division of Boston Scientific in engineering and leadership positions of increasing responsibility and was most recently the Director of Research and Development for Peripheral Interventions and Hypertension. Tony holds a Bachelors of Mechanical Engineering degree from the University of Minnesota.